Holen Sie sich die Stockscreener-App
12.45
1.22%
0.15
Handel nachbörslich:
12.69
0.24
+1.93%
Schlusskurs vom Vortag:
$12.30
Offen:
$12.05
24-Stunden-Volumen:
3.47M
Relative Volume:
1.30
Marktkapitalisierung:
$1.42B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-242.30M
KGV:
-5.0202
EPS:
-2.48
Netto-Cashflow:
$-192.10M
1W Leistung:
+8.26%
1M Leistung:
+72.20%
6M Leistung:
+51.83%
1J Leistung:
+43.27%
1-Tages-Spanne:
$12.01
$12.74
1-Wochen-Bereich:
$11.60
$12.97
52-Wochen-Spanne:
$3.72
$12.97
Cogent Biosciences Inc Stock (COGT) Company Profile
Firmenname
Cogent Biosciences Inc
Sektor
Branche
Telefon
617-945-5576
Adresse
275 WYMAN STREET, WALTHAM
Vergleichen Sie COGT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
12.45 | 1.60B | 0 | -242.30M | -192.10M | -2.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-11 | Herabstufung | Needham | Buy → Hold |
| 2024-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | Eingeleitet | Citigroup | Buy |
| 2023-12-11 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-12-08 | Eingeleitet | JP Morgan | Overweight |
| 2023-04-28 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-27 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-06-28 | Eingeleitet | Guggenheim | Buy |
| 2021-10-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-06-09 | Fortgesetzt | Jefferies | Buy |
| 2020-12-23 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Cogent Biosciences Inc Aktie (COGT) Neueste Nachrichten
What drives Cogent Biosciences Inc. stock priceOutstanding investment returns - jammulinksnews.com
Is Cogent Biosciences Inc. a good long term investmentMarket-beating performance - jammulinksnews.com
What analysts say about Cogent Biosciences Inc. stockOutstanding investment returns - jammulinksnews.com
Cogent Biosciences (NASDAQ:COGT) Given New $22.00 Price Target at Citigroup - MarketBeat
3 Stocks With Sky-High Overbought Signals: QuantumScape, Opendoor, Cogent Flash RSI Red Flags - Benzinga
When (COGT) Moves Investors should Listen - news.stocktradersdaily.com
Cogent Biosciences Inc. Stock Analysis and ForecastOutperformance with explosive growth - Autocar Professional
Cogent Biosciences (COGT) Target Price Raised by Citigroup | COG - GuruFocus
Cogent Biosciences stock hits 52-week high at 12.66 USD By Investing.com - Investing.com South Africa
Cogent Biosciences stock hits 52-week high at 12.66 USD - Investing.com
Blueprint Medicines' (BPMC) Ayvakit Faces Competition from Cogent Biosciences | BPMC Stock News - GuruFocus
Blueprint Medicines' (BPMC) Ayvakit Faces Competition from Cogen - GuruFocus
Jefferies Raises Cogent Biosciences (COGT) PT, Keeps Buy Rating - MSN
Cogent Biosciences: Analyst Maintains Buy Rating Amid Promising Trials and Strategic Advantages - AInvest
Day 11 of Gains Streak for Cogent Biosciences Stock with 67% Return (vs. 52% YTD) [7/16/2025] - Trefis
10 Best Small-Cap Stocks to Buy According to Billionaires - Insider Monkey
COGT Stock Up 62% after 10-Day Win Streak - Trefis
Mintz Advises on Cogent Biosciences’ $230 Million Public Offering - Mintz
Press Release: Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock - 富途牛牛
COGT Stock Soars on Phase III Systemic Mastocytosis Study Success - MSN
Cogent Biosciences (NASDAQ:COGT) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says - MarketBeat
Guggenheim Reiterates "Buy" Rating for Cogent Biosciences with $17 Price Target - AInvest
Cogent Biosciences (NASDAQ:COGT) Price Target Raised to $22.00 at HC Wainwright - MarketBeat
Cogent Biosciences Closes $230 Million Upsized Stock Offering - MarketScreener
Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Cogent Biosciences Announces Closing of Upsized Public - GlobeNewswire
Cogent Biosciences Secures Massive $230M Funding for Bezuclastinib Drug Development - Stock Titan
Cogent Biosciences’ Mysterious 5.6% Surge: What’s Behind the Move? - AInvest
Cogent Biosciences' 8% Surge: Unraveling the Mystery Behind the Spike - AInvest
Cogent Biosciences(COGT) Soars 6.34% on Phase III Success - AInvest
Form 424B5 Cogent Biosciences, Inc. - StreetInsider
Cogent: Positive Data In NonAdvSM Bodes Well For 2nd Half AdvSM Treatment Results (COGT) - Seeking Alpha
Cogent Biosciences: Drug Trial Triumph Sparks Stock Surge - StocksToTrade
A Quick Look at Today's Ratings for Cogent Biosciences(COGT.US), With a Forecast Between $17 to $25 - 富途牛牛
Cogent Biosciences slips after upsized $200 mln equity offering - TradingView
Cogent Biosciences Prices $200 Million Stock Offering - MarketScreener
Cogent Biosciences (COGT) Prices $200M Public Offering at $9 Per Share - GuruFocus
Cogent Biosciences Scores Analyst Praise As Mastocytosis Drug Hits Trial Goals; Retail Buzz Surges - NewsBreak: Local News & Alerts
Cogent Biosciences Secures Massive $200M Funding to Accelerate Bezuclastinib Development - Stock Titan
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock - The Manila Times
Cogent Biosciences announces pricing of upsized public offering of shares of common stock - MarketScreener
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock | COGT Stock News - GuruFocus
Cogent Biosciences stock falls on $150 million share offering By Investing.com - Investing.com India
After-hours movers: Mobileye, RxSight, Cogent Biosciences By Investing.com - Investing.com Canada
Cogent Biosciences (COGT) Sees Positive Analyst Action with Rais - GuruFocus
Cogent's Funding to Propel Bezuclastinib Development | COGT Stoc - GuruFocus
Cogent Biosciences' $150M Offering: A Risky Gamble or a Strategic Bet on Breakthrough Science? - AInvest
Cogent Biosciences stock falls on $150 million share offering - Investing.com Australia
Finanzdaten der Cogent Biosciences Inc-Aktie (COGT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):